Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase 1 ACM-CpG TLR9 agonist polymer-lipid nanoparticle for peritoneal metastases
This Phase 1, open-label, dose-escalation study (standard 3+3) tests escalating intraperitoneal injections of ACM-CpG to define safety, dose-limiting toxicities, and the maximum tolerated dose/optimal biologic dose…
NCT07658196 Exploratory - New trial
Multiple solid tumors
Phase 1 BSI-082 anti-SIRPα macrophage checkpoint antibody ± T-DXd HER2 ADC
This open-label Phase 1a/1b, two-part dose-escalation and dose-expansion study evaluates BSI-082 (a fully human anti–SIRPα monoclonal antibody that blocks the CD47–SIRPα “don’t eat me” signal to enhance…
NCT07086768 First-in-human - New trial
Multiple solid tumors
Phase 1/2 PM54 + pembrolizumab tests tubulin (microtubule) inhibition paired with PD-1 blockade.
This multicenter, open-label Phase 1/2 trial from PharmaMar evaluates PM54 (a small-molecule microtubule/tubulin inhibitor) combined with pembrolizumab (Keytruda; Merck/MSD’s PD-1–blocking monoclonal antibody) in…
NCT07644039 Exploratory - New trial
Multiple solid tumors
Phase 1/2 VMD-102 selective PKCε (protein kinase C epsilon) inhibitor in HCC and solid tumors.
This first-in-human, open-label, multicenter Phase 1/2 study sponsored by VM Discovery evaluates VMD-102, a selective PKC epsilon (PKCε) kinase inhibitor intended to suppress oncogenic PKC signaling that can promote…
NCT07636785 First-in-human - New trial
Multiple solid tumors
Phase 1 MSK‑TCR5 CD8α/β‑armored KRAS/HRAS/NRAS G12D TCR‑T therapy
This Memorial Sloan Kettering Cancer Center (MSKCC) investigator-initiated Phase 1, open-label, dose-escalation trial tests MSK‑TCR5—an autologous T‑cell receptor–engineered T‑cell product designed to recognize the…
NCT07638371 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 BLU-924 (SAR449336) pan-KRAS inhibitor in KRAS-mutant PDAC/NSCLC/CRC
This first-in-human, open-label Phase 1/2 trial tests BLU-924 (SAR449336), an oral pan-KRAS small-molecule inhibitor, as monotherapy and in combination therapy in people with metastatic, KRAS-mutant pancreatic ductal…
NCT07629960 First-in-human - New trial
Multiple solid tumors
Phase 2 TIMED trial tests PD‑1/PD‑L1 checkpoint blockade timing (morning vs afternoon).
UNC Lineberger Comprehensive Cancer Center is running this Phase 2, open-label, randomized, parallel-assignment study to test whether *time of day* changes outcomes from standard immune checkpoint inhibitors in solid…
NCT07630168 Exploratory - New trial
Multiple solid tumors
Phase 1/2 ALK201 FGFR2b-targeting ADC (TOP1 inhibitor payload) in advanced solid tumors
This first-in-human, open-label Phase 1/2 trial evaluates ALK201 monotherapy in adults with advanced/metastatic solid tumors, using sequential dose escalation (to define dose-limiting toxicities, maximum tolerated…
NCT06656390 First-in-human - New trial
Multiple solid tumors
Phase 1 GSK5533524 antibody–drug conjugate (ADC) targeting an undisclosed tumor-associated antigen
No disclosed MOA. We do not include details of trials without this basic information.
NCT07438782 First-in-human - New trial
Multiple solid tumors
Phase 1 IM-1617 undisclosed RTK–targeting ADC with TOP1 inhibitor payload in solid tumors
Immunome, Inc. is running a first-in-human, open-label Phase 1 dose-escalation (Part A) followed by dose-expansion (Part B) study to define the recommended dose/schedule and assess early antitumor activity of IM-1617…
NCT07578571 First-in-human - New trial
Multiple solid tumors
Phase 1 NEOK002 EGFR×MUC1 bispecific ADC with topoisomerase-1 inhibitor payload
NEOK Bio’s first-in-human, open-label Phase 1 study (NCT07612189) evaluates NEOK002, an EGFR- and MUC1-binding bispecific antibody-drug conjugate (ABL209) carrying an exatecan-class topoisomerase I inhibitor payload…
NCT07612189 First-in-human - New trial
Multiple solid tumors
Phase 1 BI 3819026 anti-LAYN antibody + ezabenlimab PD-1 inhibitor in solid tumors.
This first-in-human, open-label, multicenter Phase 1 dose-escalation study tests BI 3819026 (a Boehringer Ingelheim anti-LAYN/layilin antibody; LAYN is a hyaluronan-binding cell-surface protein implicated in tumor…
NCT07607678 First-in-human - New trial
Multiple solid tumors
Phase 1 CS231295 Aurora B–selective multi-kinase inhibitor in advanced solid tumors and glioma
This Phase 1, single-arm, open-label, multicenter dose-escalation study evaluates CS231295 in adults with unresectable, advanced/recurrent/metastatic solid tumors (including a glioma cohort) who have exhausted…
NCT07612488 First-in-human - New trial
Multiple solid tumors
Phase 1 NEOK001 B7-H3×ROR1 bispecific ADC targets dual tumor antigens in solid tumors.
This first-in-human, open-label Phase 1 study evaluates NEOK001 (also referenced as ABL206), a bispecific antibody-drug conjugate from NEOK Bio, Inc. designed to bind two tumor-associated surface targets—B7-H3…
NCT07612176 First-in-human - New trial
Multiple solid tumors
Phase 1/2 UI-102 cholesteryl-pullulan nanoparticle TLR7/8 agonist immunostimulant in solid tumors.
This first-in-human, open-label Phase 1/2 trial evaluates UI-102, a small-molecule Toll-like receptor 7/8 (TLR7/8) agonist formulated in a cholesteryl pullulan (CHP) nanoparticle for IV infusion, sponsored by United…
NCT07605962 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 TCR1188-ABC KRAS G12V TCR + ILT4 (LILRB2)–redirected base-edited T cells
This University of Pennsylvania first-in-human, Phase 1, open-label 3+3 dose-escalation study tests TCR1188-ABC: autologous CD4+ and CD8+ T cells that are base-edited and engineered to (1) express a high-affinity,…
NCT07594067 First-in-human - New trial
Multiple solid tumors
Phase 2 FLOT (docetaxel microtubule inhibitor) consolidation after CRT in localized EAC/EGJ
This Duke University single-arm Phase 2 study tests whether adding consolidative multi-agent chemotherapy after standard upfront chemoradiation can improve disease control and increase organ preservation (avoiding…
NCT07603375 Exploratory - New trial
Multiple solid tumors
Phase 1/1b futibatinib FGFR1–4 inhibitor + paclitaxel + ramucirumab VEGFR2 mAb in 2L gastroesophageal adenocarcinoma.
This Phase 1/1b, open-label dose-escalation/expansion study tests whether adding futibatinib (Lytgobi; an irreversible covalent FGFR1–4 tyrosine kinase inhibitor, from Taiho Oncology/Taiho Pharmaceutical) to the…
NCT07594548 Exploratory - New trial
Multiple solid tumors
Phase 1/2 IDP-001 EGFR×CDCP1 bispecific ADC (proximity-guided co-targeting)
InduPro’s Phase 1/2 open-label, sequential-assignment study evaluates IDP-001 given by IV infusion in two parts: Part 1 dose escalation across advanced/metastatic solid tumors to define safety/tolerability,…
NCT07602842 First-in-human - New trial
Multiple solid tumors
Phase 2 LATTICE radiotherapy spatially fractionated SBRT vs dose-escalated palliative RT.
Stanford University is running an unblinded, randomized Phase 2 study testing whether LATTICE radiotherapy—a spatially fractionated stereotactic technique that delivers a lower “background” dose to the full…
NCT07594431 Exploratory - New trial
Multiple solid tumors
Phase 1b/2 navlimetostat (BMS-986504) PRMT5 inhibitor + pemetrexed antifolate in MTAP-deleted tumors.
This Phase 1b/2 basket study at Northwestern University evaluates navlimetostat (BMS-986504; Bristol Myers Squibb)—an MTA-cooperative PRMT5 inhibitor that exploits the MTAP-deletion synthetic-lethality…
NCT07594626 Exploratory - New trial
Multiple solid tumors
Phase 1 JNJ-1761981 ER intratumoral extended-release cisplatin in solid tumors
This Phase 1 open-label Johnson & Johnson Enterprise Innovation study tests intratumoral JNJ-1761981 ER, an extended-release cisplatin formulation designed to deliver platinum DNA-damaging chemotherapy directly into…
NCT07525141 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 RLY-8161 trial tests an NRAS-selective small-molecule inhibitor (NRAS target)
This Phase 1 first-in-human, open-label, multicenter study evaluates RLY-8161—an NRAS-selective small-molecule inhibitor—from Relay Therapeutics in adults with unresectable Stage III/IV NRAS-mutant melanoma or other…
NCT07584226 First-in-human - New trial
Multiple solid tumors
Phase 1 Yttrium-90 (beta-emitting glass microspheres) radioembolization dose-escalation in unresectable liver tumors
Northwestern University’s MARGIN Study is a prospective, non-randomized, open-label dose-escalation trial designed to define an “ablative” absorbed-dose range for yttrium-90 (Y-90) transarterial radioembolization…
NCT07586046 Exploratory - New trial
Multiple solid tumors
Phase 1/2a PMC2129G12 intratumoral mRNA-LNP encodes EpCAM×CD3 bispecific + cytokines
This Phase 1/2a, open-label, single-arm study from IntraAb evaluates intratumoral PMC2129G12, an mRNA–lipid nanoparticle designed to drive localized, transient tumor expression of a humanized EpCAM-targeted,…
NCT07587879 First-in-human - New trial
Multiple solid tumors
Phase 1/2 DT-7012 anti-CCR8 monoclonal antibody (Treg-depleting immunotherapy) in solid tumors.
This first-in-human, multicenter, open-label Phase 1/2 study (DOMISOL; DT-7012-CLI-001) evaluates DT-7012, a CCR8-targeting monoclonal antibody designed to deplete CCR8+ intratumoral regulatory T cells (Tregs) and…
NCT06819735 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 ODM-212 pan-TEAD (Hippo/YAP–TEAD) inhibitor combinations in solid tumors
Orion Corporation (Orion Pharma) is running this open-label, multi-cohort Phase 1/2 study to define safety, tolerability, pharmacokinetics/pharmacodynamics, and early efficacy of ODM-212, an oral small-molecule…
NCT07563738 Exploratory - New trial
Multiple solid tumors
Phase 1 NPX372 B7-H7×CD3 T‑cell–engaging bispecific antibody in refractory solid tumors.
NextPoint Therapeutics’ first-in-human, open-label Phase 1 study dose-escalates NPX372, an IgG-like bispecific antibody that binds B7‑H7 (also called HHLA2/B7‑H7 axis target) on tumor cells and CD3 on T cells to…
NCT07563829 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 D3S-003 dual-state KRAS G12D inhibitor (targets GDP- and GTP-bound KRAS)
This first-in-human, open-label Phase 1 study evaluates D3S-003 monotherapy in adults with advanced/metastatic solid tumors harboring a KRAS p.G12D mutation, focusing on safety, tolerability,…
NCT07456046 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 ML261 DLL3-targeted CAR-T with CARD11–PIK3R3 “armoring” fusion in R/R SCLC/NECs.
This first-in-human, open-label Phase 1 trial (SPECTRAL-1) evaluates ML261, an autologous anti-DLL3 chimeric antigen receptor (CAR) T-cell therapy that also expresses a CARD11–PIK3R3 fusion transgene intended to…
NCT07488923 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.